Toll-like receptors in systemic autoimmune disease

Nature Reviews Immunology

Volumn 6, Issue 11, 2006, Pages 823-835

  Marshak Rothstein, Ann ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MAMMAL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; HUMANS; INTERFERON-ALPHA; LIGANDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, IMMUNOLOGICAL; TOLL-LIKE RECEPTORS;

EID: 33750369226     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1957     Document Type: Review

References (126)

1. Casciola-Rosen, L. A., Anhalt, G. & Rosen, A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179, 1317-1330 (1994).
2. Rosen, A. & Casciola-Rosen, L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ. 6, 6-12 (1999).
3. Utz, P. J., Gensler, T. J. & Anderson, P. Death, autoantigen modifications, and tolerance. Arthritis Res. 2, 101-114 (2000).
4. Plotz, P. H. The autoantibody repertoire: searching for order. Nature Rev. Immunol. 3, 73-78 (2003).
5. Medzhitov, R. & Janeway, C. A. Jr. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89-97 (2000).
6. Tsan, M.-F. & Gao, B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 76, 514-519 (2004).
7. Theofilopoulos, A. N., Baccala, R., Beutler, B. & Kono, D. H. Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307-336 (2005).
8. Preble, O. T., Black, R. J., Friedman, R. M., Klippel, J. H. & Vilcek, J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 216, 429-431 (1982).
9. Ronnblom, L. E., Alm, G. V. & Oberg, K. E. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J. Intern. Med. 227, 207-210 (1990).
10. Gota, C. & Calabrese, L. Induction of clinical autoimmune disease by therapeutic interferon-α. Autoimmunity 36, 511-518 (2003).
11. Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003).
12. Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 17, 711-723 (2003).
13. Banchereau, J., Pascual, V. & Palucka, A. K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20, 539-550 (2004).
14. Rönnblom, L. & Alm, G. V. A pivotal role for the natural interferon α-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J. Exp. Med. 194, F59-F63 (2001).
15. Vallin, H., Blomberg, S., Alm, G. V., Cederblad, B. & Rönnblom, L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-α (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 115, 196-202 (1999).
16. Rönnblom, L. & Alm, G. V. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 22, 427-431 (2001). Excellent review of the studies that establish a key role for nucleic-acid-containing immune complexes in the induction of IFNα production by pDCs.
17. Lovgren, T., Eloranta, M. L., Bave, U., Alm, G. V. & Rönnblom, L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50, 1861-1872 (2004).
18. Amigorena, S. & Bonnerot, C. Role of B-cell and Fc receptors in the selection of T cell epitopes. Curr. Opin. Immunol. 10, 88-92 (1998).
19. Bave, U. et al. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J. Immunol. 171, 3296-3302 (2003).
20. Kadowaki, N. et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863-869 (2001).
21. Krieg, A. M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549 (1995).
22. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
23. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531 (2004).
24. Heil, F. et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526-1529 (2004).
25. Lund, J. M. et al. TLR7: a new sensor of viral infection. Proc. Natl Acad. Sci. USA 101, 6835-6836 (2004).
26. Ahmad-Nejad, P. et al. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32, 1958-1968 (2002).
27. Boule, M. W. et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199, 1631-1640 (2004).
28. Means, T. K. et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115, 407-417 (2005). References 27 and 28 were the first to show the involvement of TLRs in the activation of DCs by DNA-containing immune complexes.
29. Honda, K. et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434, 1035-1040 (2005).
30. Vollmer, J. et al. Autoantigen binding sites within small nuclear RNAs induce innate immunity through Toll-like receptors 7 and 8. J. Exp. Med. 202, 1575-1585 (2005). Shows that activation of TLR7 by snRNAs is sequence specific.
31. Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131-1139 (2005).
32. Lovgren, T. et al. Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum. 54, 1917-1927 (2006).
33. Savarese, E. et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107, 3229-3234 (2006).
34. Rifkin, I. R., Leadbetter, E. A., Busconi, L., Viglianti, G. & Marshak-Rothstein, A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204, 27-42 (2005).
35. Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374-1377 (2003).
36. Yurasov, S. et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201, 703-711 (2005).
37. Chen, C. J. et al. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J. Rheumatol. 32, 44-47 (2005).
38. Hunziker, L. et al. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nature Immunol. 4, 343-349 (2003).
39. McClain, M. T. et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nature Med. 11, 85-89 (2005).
40. Wang, Y. & Krieg, A. M. Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. Int. Immunol. 15, 223-231 (2003).
41. Bekeredjian-Ding, I. B. et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174, 4043-4050 (2005).
42. Brummel, R., Roberts, T. L., Stacey, K. J. & Lenert, P. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice. Eur. J. Immunol. 36, 1951-1962 (2006).
43. Jacobson, B. A. et al. An isotype switched and somatically mutated rheumatoid factor clone isolated from a MRL-lpr/lpr mouse exhibits limited intraclonal affinity maturation. J. Immunol. 152, 4489-4499 (1994).
44. Hannum, L. G., Ni, D., Haberman, A. M., Weigert, M. G. & Shlomchik, M. J. A disease-related rheumatoid factor autoantibody is not tolerized in a normal mouse: implications for the origins of autoantibodies in autoimmune disease. J. Exp. Med. 184, 1269-1278 (1996).
45. Leadbetter, E. A. et al. Chromatin-IgG complexes activate autoreactive B cells by dual engagement of sIgM and Toll-like receptors. Nature 416, 603-607 (2002).
46. Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined BCR/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171-1177 (2005). References 45 and 46 were the first to show that the in vitro activation of autoreactive B cells by DNA- and RNA-containing immune complexes depends on TLR9 and TLR7, respectively.
47. Busconi, L. et al. DNA and RNA autoantigens as autoadjuvants. J. Endotoxin Res. (in the press).
48. Viglianti, G. A. et al. Activation of autoreactive B cells by CpG dsDNA. Immunity 19, 837-847 (2003).
49. Messina, J. P., Gilkeson, G. S. & Pisetsky, D. S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147, 1759-1764 (1991).
50. Sun, S., Beard, C., Jaenisch, R., Jones, P. & Sprent, J. Mitogenicity of DNA from different organisms for murine B cells. J. Immunol. 159, 3119-3125 (1997).
51. Stacey, K. J. et al. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J. Immunol. 170, 3614-3620 (2003).
52. Gursel, I. et al. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J. Immunol. 171, 1393-1400 (2003).
53. Barton, G. M., Kagan, J. C. & Medzhitov, R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nature Immunol. 7, 49-56 (2006).
54. Richardson, B. et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33, 1665-1673 (1990).
55. Sano, H. & Morimoto, C. DNA isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content. J. Immunol. 128, 1341-1345 (1982).
56. Cornacchia, E. et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140, 2197-2200 (1988).
57. Lunec, J., Herbert, K., Blount, S., Griffiths, H. R. & Emery, P. 8-Hydroxydeoxyguanosine: a marker of oxidative DNA damage in systemic lupus erythematosus. FEBS Lett. 348, 131-138 (1994).
58. Cooke, M. S., Mistry, N., Wood, C., Herbert, K. E. & Lunec, J. Immunogenicity of DNA damaged by reactive oxygen species - implications for anti-DNA antibodies in lupus. Free Radic. Biol. Med. 22, 151-159 (1997).
59. Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165-175 (2005). Shows that post-transcriptional modification of mammalian RNA interferes with the ability of ssRNA to engage TLR7 effectively.
60. Emerit, I. & Michelson, A. M. Mechanism of photosensitivity in systemic lupus erythematosus patients. Proc. Natl Acad. Sci. USA 78, 2537-2540 (1981).
61. Andrade, F., Casciola-Rosen, L. A. & Rosen, A. Generation of novel covalent RNA-protein complexes in cells by ultraviolet B irradiation: implications for autoimmunity. Arthritis Rheum. 52, 1160-1170 (2005).
62. Caricchio, R., McPhie, L. & Cohen, P. L. Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J. Immunol. 171, 5778-5786 (2003).
63. Christensen, S. R. et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202, 312-331 (2005).
64. Christensen, S. R. et al. TLR7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428 (2006). Shows that TLR7-deficient autoimmune-prone mice do not produce antibodies that react with RNA-associated autoantigens and do not have exacerbated clinical disease.
65. Wu, X. & Peng, S. L. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 54, 336-342 (2006).
66. Yu, P. et al. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int. Immunol. 18, 1211-1219 (2006).
67. Lartigue, A. et al. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J. Immunol. 177, 1349-1354 (2006). References 63-67 show that TLR9-deficient autoimmune-prone mice develop more severe clinical disease than do TLR9-sufficient mice, even though the titre of antibodies that react with dsDNA or nucleosomes is reduced.
68. Ehlers, M., Fukuyama, H., McGaha, T. L., Aderem, A. & Ravetch, J. V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203, 553-561 (2006). Shows that TLR9-deficient autoimmune-prone mice do not make DNA-specific antibodies of the pathogenic isotypes IgG2a and IgG2b.
69. Peng, S. L., Szabo, S. J. & Glimcher, L. H. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl Acad. Sci. USA 99, 5545-5550 (2002).
70. Berland, R. et al. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 25, 429-440 (2006).
71. Pisitkun, P. et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312, 1669-1672 (2006).
72. Subramanian, S. et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl Acad. Sci. USA 103, 9970-9975 (2006). References 71 and 72 show that the Yaa mutation results in a twofold increase in the expression of TLR7 and that Yaa affects autoimmune-prone B cells directly, by skewing the autoantibody repertoire to antibodies that recognize RNA-associated autoantigens.
73. -/- mice. J. Exp. Med. 195, 1167-1174 (2002).
74. Kirou, K. A. et al. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52, 1491-1503 (2005).
75. Lenert, P. S. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res. Ther. 8, 203-214 (2006).
76. Wallace, D. J. in Dubois' Lupus Erythematosus (eds Wallace, D. J. & Hahn, B. H.) 563-573 (Lea & Febiger, Philadelphia, 1987).
77. Tye, M. J., White, H., Appel, B. & Ansell, H. B. Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine, and chloroquine. N. Engl. J. Med. 260, 63-66 (1959).
78. Macfarlane, D. E. & Manzel, L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine and structurally related compounds. J. Immunol. 160, 1122-1131 (1998).
79. Hacker, H. et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17, 6230-6240 (1998).
80. Yi, A.-K. et al. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160, 4755-4761 (1998).
81. Krieg, A. M. CpG motifs: the active ingredient in bacterial extracts? Nature Med. 9, 831-835 (2003).
82. Krieg, A. M. et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl Acad. Sci. USA 95, 12631-12636 (1998).
83. Ashman, R. F., Goeken, J. A., Drahos, J. & Lenert, P. Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int. Immunol. 17, 411-420 (2005).
84. Patole, P. S. et al. G-rich DNA suppresses systemic lupus. J. Am. Soc. Nephrol. 16, 3273-3280 (2005).
85. Dong, L., Ito, S., Ishii, K. J. & Klinman, D. M. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice. Arthritis Rheum. 52, 651-658 (2005).
86. Takaoka, A. et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434, 243-249 (2005).
87. Schoenemeyer, A. et al. The interferon regulatory factor, IRF5, is a central mediator of Toll-like receptor 7 signaling. J. Biol. Chem. 280, 17005-17012 (2005).
88. Sigurdsson, S. et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76, 528-537 (2005).
89. Graham, R. R. et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nature Genet. 38, 550-555 (2006). References 88 and 89 identify variants of IRF5, a transcription factor downstream of TLR7 and TLR9, to be an important factor in susceptibility to SLE in humans.
90. Joosten, L. A. B. et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J. Immunol. 171, 6145-6153 (2003).
91. Deng, G. M., Nilsson, I. M., Verdrengh, M., Collins, L. V. & Tarkowski, A. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nature Med. 5, 702-705 (1999).
92. Waldner, H., Collins, M. & Kuchroo, V. K. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113, 990-997 (2004).
93. Kerfoot, S. M. et al. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J. Immunol. 173, 7070-7077 (2004).
94. Ichikawa, H. T., Williams, L. P. & Segal, B. M. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169, 2781-2787 (2002).
95. Eriksson, U. et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nature Med. 9, 1484-1490 (2003).
96. Lang, K. S. et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nature Med. 11, 138-145 (2005).
97. Yumoto, H. et al. Sensitization of human aortic endothelial cells to lipopolysaccharide via regulation of Toll-like receptor 4 by bacterial fimbria-dependent invasion. Infect. Immun. 73, 8050-8059 (2005).
98. Kiechl, S. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185-192 (2002).
99. Kilding, R. et al. A biologically important single nucleotide polymorphism within the Toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin. Exp. Rheumatol. 21, 340-342 (2003).
100. Choe, J.-Y., Crain, B., Wu, S. R. & Corr, M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. J. Exp. Med. 197, 537-542 (2003).
101. Prinz, M. et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 116, 456-464 (2006).
102. Iliev, A. I., Stringaris, A. K., Nau, R. & Neumann, H. Neuronal injury mediated via stimulation of microglial Toll-like receptor-9 (TLR9). FASEB J. 18, 412-414 (2004).
103. Leemans, J. C. et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Invest. 115, 2894-2903 (2005).
104. Shishido, T. et al. Toll-like receptor 2 modulates ventricular remodeling after myocardial infarction. Circulation 108, 2905-2910 (2003).
105. Oyama, J. et al. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 109, 784-789 (2004).
106. Jiang, D. et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nature Med. 11, 1173-1179 (2005).
107. Tan, E. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 44, 93-151 (1989).
108. Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
109. Verthelyi, D. & Zeuner, R. A. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 24, 519-522 (2003).
110. Hartmann, G. et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33, 1633-1641 (2003).
111. Li, M. et al. An essential role of the NF-κB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 166, 7128-7135 (2001).
112. Vabulas, R. M., Wagner, H. & Schild, H. Heat shock proteins as ligands of Toll-like receptors. Curr. Top. Microbiol. Immunol. 270, 169-184 (2002).
113. Liu, B. et al. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc. Natl Acad. Sci. USA 100, 15824-15829 (2003).
114. Park, J. S. et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377 (2004).
115. Termeer, C. et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med. 195, 99-111 (2002).
116. Taylor, K. R. et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J. Biol. Chem. 279, 17079-17084 (2004).
117. Okamura, Y. et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 276, 10229-10233 (2001).
118. Miller, Y. I. et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278, 1561-1568 (2003).
119. Johnson, G. B., Brunn, G. J. & Platt, J. L. An endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J. Immunol. 172, 20-24 (2004).
120. Smiley, S. T., King, J. A. & Hancock, W. W. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J. Immunol. 167, 2887-2894 (2001).
121. Roelofs, M. F. et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J. Immunol. 176, 7021-7027 (2006).
122. Brentano, F., Schorr, O., Gay, R. E., Gay, S. & Kyburz, D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 52, 2656-2665 (2005).
123. Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
124. Lien, E. & Ingalis, R. R. Toll-like receptors. Crit. Care Med. 30, S1-S11 (2002).
125. Zhang, D. et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 303, 1522-1526 (2004).
126. Yarovinsky, F. et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 308, 1626-1629 (2005).